Generic Drugs

A study has found a new biomarker of schizophrenia, which could also serve as a drug target for treating cognitive symptoms such as disorganised thinking or executive function. Schizophrenia is a mental health disorder marked by an impaired ability to perceive and interpret reality and can involve delusions and disorganised thinking, or cognitive symptoms. Researchers from the US' Northwestern University said that schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms. "A lot of people with schizophrenia cannot integrate well into society because of these cognitive deficits," author Peter Penzes, professor of neuroscience, pharmacology and psychiatry and behavioral sciences at Northwestern University's school of medicine, said. "Our discovery could solve these challenges by establishing the basis of a revolutionary and completely novel treatment strategy through a tandem biomarker-peptide therapeutic approach," Penzes ...

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Aurobindo Pharma subsidiary Eugia Pharma has launched generic Pomalidomide Capsules in the US, one of the first-to-file applicants for the drug, expanding its oncology portfolio

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

Sun Pharmaceutical Industries expects pressure on its US generics business to ease as compliance improves, while focusing growth efforts on innovation-led therapies

Analysts say the US move to link drug prices to the lowest global benchmarks targets patented medicines, limiting near-term risks for India's largely generic-focused exporters

NMC has asked medical colleges to set up sub-committees to monitor prescription practices and stress clear, legible handwriting as part of medical training.

Health Canada's non-compliance notice may delay DRL's semaglutide generic launch by 8-12 months, say analysts; shares fall over 4 per cent on Thursday

The announcement comes a day after Lupin said the US FDA had inspected its Nagpur injectable facility between September 8 and 16, issuing six observations

A Parliamentary panel has flagged that a substantial segment of cancer drugs are still beyond the ambit of current price control mechanisms and recommended measures to include the widest possible range of cancer drugs by expanding the scope of the Drugs Prices Control Order. In its 163rd report presented on Wednesday, the Committee on Petitions, Rajya Sabha, headed by Narain Dass Gupta stressed that regular and comprehensive market assessments should be instituted to monitor prevailing drug prices and availability trends. Though significant steps have been taken in recent years towards strengthening the regulatory framework for governing the pricing of cancer drugs and promote affordability, a substantial segment of such drugs still remain beyond the ambit of current price control mechanisms, it said. The Committee noted that with the notification of NLEM, 2022, the number of anti-cancer medicines under price control has increased from 40 (in 2011) to 63 (in 2022). However, a ...

Government may fix retail prices for empagliflozin combinations as generic versions flood the market following the drug's patent expiry, causing price drops

The decision follows years of financial losses in the US generics business, including loss of nearly $8 million in FY 2025, Wockhardt said in a BSE filing

The product, launched in the US market, is a generic version of Atrovent and part of Lupin's plan to scale complex generics revenue share to 62 per cent by FY30

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

India has not accepted the demand of the UK for inclusion of a 'data exclusivity' provision in the free trade agreement, announced on May 6, in a bid to protect the interests of the domestic generic drugs industry, an official said. During the negotiations, the UK had asked to include this provision in the trade pact. "But India has not accepted that. There is no fear for the Indian generic industry from this agreement. In fact, it is our very important objective to see that the generic drug industry flourishes," the official said. The sector plays a key role in India's exports, which are also growing. Data exclusivity provides protection to the technical data generated by innovator companies to prove the usefulness of their products. In the pharmaceutical sector, drug companies generate data through expensive global clinical trials to prove the efficacy and safety of their new medicine. By gaining exclusive rights over this data, innovator companies can prevent their competitors

Pharma industry veteran said that the US wanting to encourage local production is a very natural thing to do

Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat conditions related to high pressure in the eye. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Latanoprostene Bunod Ophthalmic Solution, (0.024 per cent), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Bausch and Lomb, Inc's Vyzulta ophthalmic solution, it added. The product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity, Gland Pharma said. According to IQVIA, the product had sales of around USD 171 million in the US for the 12 months ending February 2025. Shares of Gland Pharma on Wednesday ended 1.04 per cent down at Rs 1,398.35 apiece on the BSE.

Trump tariffs: Blue Jet Healthcare, Aarti Pharmalabs, Marksans Pharma, Ipca, Wockhardt, Ami Organics, Biocon, Piramal Pharma, Lupin, Laurus Labs and Gland Pharma dropped in the range of 3% to 10%

Innovator drug price is Rs 22-72 lakh per year; Analysts forecast Natco to price generic drug at Rs 3,000 per year